FIELD: biotechnology.
SUBSTANCE: invention relates to separation of factor VIII protein (FVIII) from von Willebrand factor protein (vWF) and production of modified blood plasma, and can be used in medicine for treating diseases, requiring coagulation activity reduction, or FVIII activity determination in the sample. Methods include bringing a first composition, e.g. blood plasma containing FVIII and vWF, into contact with VIIISelect affinity resin containing a FVIII-affinity ligand, and a matrix, separating affinity resin from the mixture to produce a modified first composition and a second composition containing an affinity resin and a FVIII and vWF complex. Amount of VWF in the first composition is higher than the amount of FVIII protein, and the ratio of the volume of the first composition to the volume of the resin is in range of 5:1 to 70:1.
EFFECT: invention enables to obtain a modified blood plasma in which the FVIII concentration is less than 4 % of the average plasma FVIII concentration in a healthy human donor.
16 cl, 16 tbl, 9 ex, 11 dwg
Title | Year | Author | Number |
---|---|---|---|
METHOD OF PURIFYING COAGULATION FACTOR VIII | 2009 |
|
RU2698392C2 |
METHOD FOR PURIFICATION OF BLOOD-COAGULATION FACTOR VIII | 2009 |
|
RU2567811C2 |
RECOMBINANT PLASMID DNA pAP227 CODING POLYPEPTIDE OF RECOMBINANT FACTOR VIII OF HUMAN BLOOD COAGULABILITY, LINE OF CELLS Cricetulus griseus CHO, 2H5-PRODUCER OF RECOMBINANT FACTOR VIII OF HUMAN BLOOD COAGULABILITY, AND METHOD FOR OBTAINING POLYPEPTIDE HAVING ACTIVITY OF RECOMBINANT FACTOR VIII | 2012 |
|
RU2500818C1 |
METHOD OF PRODUCING FACTOR VIII, HAVING IMPROVED RATIO FVIII:C/FVIII:AG | 2015 |
|
RU2695428C2 |
MODIFIED VON WILLEBRAND FACTOR WITH PROLONGED HALF-CYCLE IN VIVO, USING IT AND METHODS FOR PREPARING | 2009 |
|
RU2528855C2 |
METHOD OF PRODUCING POWDER CONTAINING PROTEIN WHICH IS HUMAN BLOOD COAGULATION FACTOR AND LACTIC ACID-BASED POLYMER | 2016 |
|
RU2702740C2 |
CHEMERIC IMPROVED RECOMBINANT FACTOR VIII | 2015 |
|
RU2647769C2 |
PREPARATIONS CONTAINING VON WILLEBRAND FACTOR (vWF) AND METHODS, KITS AND APPLICATIONS RELATED TO THEM | 2010 |
|
RU2579977C2 |
METHOD FOR EVALUATING REACTION OF BLOOD COAGULATION | 2013 |
|
RU2683933C2 |
PURIFICATION OF FACTOR VIII SUBTYPES | 2018 |
|
RU2800431C2 |
Authors
Dates
2020-10-23—Published
2017-02-10—Filed